Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Phytother Res ; 35(3): 1585-1596, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33118665

RESUMEN

The rhizome of Belamcanda chinensis possesses antiinflammatory and antioxidant activities. However, the effect of irigenin, isolated from the rhizome of B. chinensis, on 1-methyl-4-phenylpyridinium (MPP+ )-induced neurotoxicity is unknown. MTT assay showed that MPP+ exposure dose dependently inhibited the viability of mouse microglia BV-2 cells, whereas irigenin suppressed MPP+ -induced viability reduction. The production of nitric oxide, prostaglandin E2, tumor necrosis factor-α and interleukin-6 were increased by MPP+ treatment, which were abolished by irigenin treatment. Irigenin-attenuated MPP+ -induced increase of malondialdehyde content and activities of superoxide dismutase, catalase and glutathione peroxidase in BV-2 cells. Irigenin treatment also repressed apoptosis, caspase-3/7 activity and Cytochrome C expression in MPP+ -challenged BV-2 cells. Interestingly, irigenin activated the Keap1/Nrf2 pathway in MPP+ -induced BV-2 cells. Nrf2 knockdown attenuated the effects of irigenin on MPP+ -induced viability reduction, inflammation, oxidative stress and apoptosis in BV-2 cells. In conclusion, irigenin alleviated MPP+ -induced neurotoxicity in BV-2 cells through regulating the Keap1/Nrf2 pathway.


Asunto(s)
1-Metil-4-fenilpiridinio/efectos adversos , Isoflavonas/uso terapéutico , Proteína 1 Asociada A ECH Tipo Kelch/metabolismo , Síndromes de Neurotoxicidad/tratamiento farmacológico , Síndromes de Neurotoxicidad/etiología , Anciano , Animales , Humanos , Isoflavonas/farmacología , Ratones
2.
Food Funct ; 10(9): 6009-6019, 2019 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-31482900

RESUMEN

The major bioactive ingredient THSG of Polygonum multiflorum is well established for its anti-oxidation, anti-aging and anti-inflammation properties. Increasing evidence supports the capacity of THSG to ameliorate the biochemistry of neurotrophins and their downstream signaling axis in mouse models to attenuate neurodegenerative diseases such as Alzheimer's and Parkinson's disease. In this study, the neuroprotective effects of THSG were studied in vitro and in vivo. In cultured mesencephalic dopamine neurons and SH-SY5Y cell line, it was found that THSG protected the integrity of the cell body and neurite branching from MPP+-induced toxicity by restoring the expression of FGF2 and BDNF and their downstream signaling pathways to inhibit apoptosis and promote cell survival. The inhibition of Akt signaling by LY294002 or TrkB activity by K252a eliminated the neuroprotective effects of THSG. In the MPTP-induced mouse models of Parkinson's disease, THSG ameliorated the animal behaviors against MPTP-induced neurotoxicity, which was demonstrated by the pole test and the tail suspension test. Biochemical and immunohistochemical analysis verified the THSG-mediated restoration of the FGF2-Akt and BDNF-TrkB signaling axis in the substantia nigra and corpus striatum and the recovery of dopaminergic neurons. These results establish the neuroprotective effects of THSG in vitro and in vivo and unravel the underlying mechanism against toxin-induced neural atrophy, providing a new avenue for the use and pharmacological research of edible medicine for anti-neurodegenerative diseases.


Asunto(s)
Factor Neurotrófico Derivado del Encéfalo/metabolismo , Medicamentos Herbarios Chinos/administración & dosificación , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Glucósidos/administración & dosificación , Glicoproteínas de Membrana/metabolismo , Fármacos Neuroprotectores/administración & dosificación , Enfermedad de Parkinson/tratamiento farmacológico , Proteínas Tirosina Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Estilbenos/administración & dosificación , 1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/efectos adversos , 1-Metil-4-fenilpiridinio/efectos adversos , Animales , Apoptosis/efectos de los fármacos , Factor Neurotrófico Derivado del Encéfalo/genética , Supervivencia Celular/efectos de los fármacos , Neuronas Dopaminérgicas/citología , Neuronas Dopaminérgicas/efectos de los fármacos , Fallopia multiflora/química , Factor 2 de Crecimiento de Fibroblastos/genética , Humanos , Masculino , Glicoproteínas de Membrana/genética , Ratones , Ratones Endogámicos C57BL , Enfermedad de Parkinson/genética , Enfermedad de Parkinson/metabolismo , Proteínas Tirosina Quinasas/genética , Proteínas Proto-Oncogénicas c-akt/genética , Transducción de Señal/efectos de los fármacos
3.
Food Chem Toxicol ; 133: 110765, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31430510

RESUMEN

Oridonin (ORI) is a natural diterpenoid presented in some medicinal plants. The effects of pre-treatments from ORI against MPP+- or kainic acid (KA)-induced damage in nerve growth factor (NGF)-differentiated PC12 cells were investigated. Results showed that pre-treatments of ORI at 0.25-2 µM enhanced the viability and plasma membrane integrity of NGF-differentiated PC12 cells. MPP+ or KA exposure down-regulated Bcl-2 mRNA expression, up-regulated Bax mRNA expression, increased caspase-3 activity and decreased Na+-K+ ATPase activity. ORI pre-treatments at test concentrations reversed these changes. ORI pre-treatments decreased reactive oxygen species production, raised glutathione level, and increased glutathione peroxidase, glutathione reductase and catalase activities in MPP+ or KA treated cells. ORI pre-treatments lowered tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and prostaglandin E2 levels in MPP+ or KA treated cells. ORI also diminished MPP+ or KA induced increase in nuclear factor-κB binding activity. MPP+ exposure suppressed tyrosine hydroxylase (TH) mRNA expression and decreased dopamine content. KA exposure reduced glutamine synthetase (GS) mRNA expression, raised glutamate level and lowered glutamine level. ORI pre-treatments at 0.5-2 µM up-regulated mRNA expression of TH and GS, restored DA and glutamine content. These findings suggested that oridonin was a potent neuro-protective agent against Parkinson's disease and seizure.


Asunto(s)
1-Metil-4-fenilpiridinio/efectos adversos , Diterpenos de Tipo Kaurano/farmacología , Ácido Kaínico/efectos adversos , Fármacos Neuroprotectores/farmacología , Animales , Proteínas Reguladoras de la Apoptosis/genética , Proteínas Reguladoras de la Apoptosis/metabolismo , Membrana Celular/metabolismo , Supervivencia Celular/efectos de los fármacos , Citocinas/genética , Citocinas/metabolismo , Diterpenos de Tipo Kaurano/toxicidad , Regulación hacia Abajo/efectos de los fármacos , Glutamato-Amoníaco Ligasa/genética , Glutamato-Amoníaco Ligasa/metabolismo , Fármacos Neuroprotectores/toxicidad , Estrés Oxidativo/efectos de los fármacos , Células PC12 , ARN Mensajero/metabolismo , Ratas , Especies Reactivas de Oxígeno/metabolismo , Tirosina 3-Monooxigenasa/genética , Tirosina 3-Monooxigenasa/metabolismo , Regulación hacia Arriba/efectos de los fármacos
4.
BMC Complement Altern Med ; 15: 151, 2015 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-25994206

RESUMEN

BACKGROUND: Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by a loss of dopaminergic neurons in the substantia nigra, decreased striatal dopamine levels, and consequent extrapyramidal motor dysfunction. The purpose of this study was to investigate potential in vivo protective effects of Duzhong against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), as well as the bioactive constituents against 1-methyl-4-phenylpyridinium (MPP(+)) toxicity in vitro. METHODS: Male C57BL/6 mice were intraperitoneally administrated five consecutive injections of MPTP every 24 h at a dose of 30 mg/kg to induce an in vivo PD model. Pole and traction tests were performed in mice to evaluate motor deficits and bradykinesia after the final MPTP administration. The striatal levels of dopamine and its metabolites, 3,4-dihydroxyphenylacetic acid and homovanilic acid, were measured using a High-performance liquid chromatography-electrical conductivity detector. To further explore the bioactive constituents and protective mechanisms of Duzhong, seven compounds from Duzhong were tested on MPP(+)-treated SH-SY5Y cell lines in vitro. A proteasome enzymatic assay and Cell Counting Kit-8 were performed to examine proteasomal activity and cell viability of Duzhong-treated cells, respectively, after exposure to MPP(+) and proteasome inhibitor MG132. RESULTS: Duzhong antagonized the loss of striatal neurotransmitters and relieved the associated anomaly in ambulatory locomotor activity in PD mice after a 3-day pre-treatment of Duzhong crude extract. The five Duzhong compounds attenuated MPP(+)-induced dysfunction of protease activity and reduced MG132-induced cytotoxicity. CONCLUSION: Duzhong could serve as a potential candidate for PD treatment, and its mechanism involves the amelioration of the ubiquitin-proteasome system.


Asunto(s)
Eucommiaceae/química , Intoxicación por MPTP/metabolismo , Fármacos Neuroprotectores/uso terapéutico , Enfermedad de Parkinson/metabolismo , Fitoterapia , Complejo de la Endopetidasa Proteasomal/metabolismo , Ubiquitina/metabolismo , 1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/efectos adversos , 1-Metil-4-fenilpiridinio/efectos adversos , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Línea Celular , Supervivencia Celular/efectos de los fármacos , Cromatografía Líquida de Alta Presión , Dopamina/metabolismo , Intoxicación por MPTP/complicaciones , Intoxicación por MPTP/tratamiento farmacológico , Masculino , Ratones , Ratones Endogámicos C57BL , Trastornos Motores/tratamiento farmacológico , Trastornos Motores/etiología , Trastornos Motores/metabolismo , Fármacos Neuroprotectores/farmacología , Neurotransmisores/metabolismo , Enfermedad de Parkinson/tratamiento farmacológico , Trastornos Parkinsonianos/tratamiento farmacológico , Trastornos Parkinsonianos/metabolismo , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico
5.
Biol Pharm Bull ; 37(2): 274-85, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24305623

RESUMEN

Parkinson's disease (PD) is the second most common neurodegenerative disease. Although the etiology of PD is not completely understood, it is well-documented that oxidative stress and Ca(2+)-mediated cellular damage play important roles in the progression of PD. 2-[[(1,1-Dimethylethyl)oxidoimino]-methyl]-3,5,6-trimethylpyrazine (TBN), a novel nitrone derivative of tetramethylpyrazine, has shown significant therapeutic effects in stroke models due to its multiple functions, including calcium overload blockade and free radical-scavenging. In this study, we investigated the neuroprotective and neurorescue effects of TBN on various in vitro and in vivo models of PD and explored its possible mechanisms of action. The results show that TBN exerted significant neuroprotection on 1-methyl-4-phenylpyridinium (MPP(+))-induced damage in SH-SY5Y cells and primary dopaminergic neurons, as well as on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neuron loss in zebrafish (TBN and MPTP were added simultaneously into the fish embryo medium and the treatment period was 48 h). In the MPTP-induced mouse and 6-hydroxydopamine (6-OHDA)-induced rat PD models, TBN administrated orally twice daily for 14 d (3 d post-MPTP lesion in mice and 7 d post-6-OHDA lesion in rats) exhibited remarkable neurorescue effects to increase the number of dopaminergic neurons. In addition, TBN improved apomorphine-induced rotational behavior in the 6-OHDA-lesioned PD rats. TBN suppressed the MPP(+)-induced intracellular reactive oxygen species (ROS) in SH-SY5Y cells, increased the superoxide dismutase (SOD) activity and glutathione (GSH) concentration in the substantial nigra of MPTP-treated mice. These data indicate that TBN protects and rescues dopaminergic neurons from MPP(+) and MPTP/6-OHDA-induced damage by reducing ROS and increasing cellular antioxidative defense capability.


Asunto(s)
Neuronas Dopaminérgicas/efectos de los fármacos , Ligusticum/química , Fármacos Neuroprotectores/uso terapéutico , Óxidos de Nitrógeno/uso terapéutico , Enfermedad de Parkinson/tratamiento farmacológico , Fitoterapia , Pirazinas/uso terapéutico , 1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/efectos adversos , 1-Metil-4-fenilpiridinio/efectos adversos , Animales , Antioxidantes/metabolismo , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Conducta Animal/efectos de los fármacos , Modelos Animales de Enfermedad , Dopamina/metabolismo , Neuronas Dopaminérgicas/metabolismo , Humanos , Masculino , Fármacos Neuroprotectores/farmacología , Óxidos de Nitrógeno/farmacología , Estrés Oxidativo/efectos de los fármacos , Oxidopamina , Enfermedad de Parkinson/etiología , Enfermedad de Parkinson/metabolismo , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Pirazinas/farmacología , Ratas , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/metabolismo , Sustancia Negra/efectos de los fármacos , Sustancia Negra/metabolismo , Pez Cebra
6.
Zhong Xi Yi Jie He Xue Bao ; 10(12): 1427-32, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23257137

RESUMEN

OBJECTIVE: To observe the protective effect of echinacoside on mitochondrial fragmentation, mitophagy and cell apoptosis in human neuroblastoma SH-SY5Y cell line exposed to 1-methyl-4-phenylpyridinium (MPP(+)). METHODS: The MPP(+) -treated SH-SY5Y cells were divided into control and drug groups. The cell apoptosis was determined by flow cytometry analysis. The alterations in mitochondrial morphology were observed, and the changes in mitochondrial membrane potential and mitophagy were measured. RESULTS: MPP(+) induced severe mitochondrial fragmentation in SH-SY5Y cells. Mitochondrial membrane potential was significantly reduced (P<0.05), which further led to mitophagy and cell apoptosis in SH-SY5Y cells treated with MPP(+) (P<0.05); mitochondrial depolarization, mitophagy and cell apoptosis in echinacoside-treated groups were significantly suppressed (P<0.05), but mitochondrial fragmentation was not affected (P>0.05). CONCLUSION: MPP(+) can cause severe damage to mitochondrial morphology and the function in SH-SY5Y cells, and echinacoside selectively reverse mitochondrial function and cell apoptosis, yet there is no effect on mitochondrial morphology.


Asunto(s)
Apoptosis/efectos de los fármacos , Glicósidos/farmacología , Mitocondrias/efectos de los fármacos , Mitofagia/efectos de los fármacos , 1-Metil-4-fenilpiridinio/efectos adversos , Línea Celular Tumoral , Humanos , Mitocondrias/metabolismo
7.
Biol Pharm Bull ; 26(12): 1668-73, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14646168

RESUMEN

Ginseng radix, the root of Panax ginseng C. A. MEYER (Araliaceae), is one of the best-known Oriental medicinal herbs with numerous therapeutic applications. To investigate whether Ginseng radix possesses a protective effect against 1-methyl-4-phenylpyridine (MPP(+))-induced cytotoxicity in neuronal cells, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, flow cytometry, DNA fragmentation assay, reverse transcription-polymerase chain reaction (RT-PCR), Western blotting, and caspase-3 enzyme assay were performed on PC12 neuronal cells. Cells treated with MPP(+) exhibited various apoptotic features, while cell pretreated with Ginseng radix prior to MPP(+) exposure showed a decrease in the occurrence of apoptotic features. These results suggest that Ginseng radix may exert a protective effect against MPP(+)-induced apoptosis in PC12 cells.


Asunto(s)
1-Metil-4-fenilpiridinio/efectos adversos , Apoptosis/efectos de los fármacos , Células PC12 , Panax/química , Extractos Vegetales/farmacología , 1-Metil-4-fenilpiridinio/antagonistas & inhibidores , 1-Metil-4-fenilpiridinio/farmacocinética , Animales , Western Blotting , Caspasa 3 , Inhibidores de Caspasas , Caspasas/efectos de los fármacos , Caspasas/metabolismo , Ciclo Celular/efectos de los fármacos , Forma de la Célula/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Fragmentación del ADN/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Medicamentos Herbarios Chinos/farmacología , Genes p53/genética , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Extractos Vegetales/química , Extractos Vegetales/uso terapéutico , Raíces de Plantas/química , Plantas Medicinales/química , Proteínas Proto-Oncogénicas c-bcl-2/antagonistas & inhibidores , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Ratas , Sales de Tetrazolio/metabolismo , Tiazoles/metabolismo , Factores de Tiempo , Proteína p53 Supresora de Tumor/antagonistas & inhibidores , Proteína p53 Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/metabolismo , Agua , Proteína X Asociada a bcl-2
8.
Neuropharmacology ; 42(8): 1056-64, 2002 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12128007

RESUMEN

The prevalence of Parkinson's disease is higher in males than in females. Although the reason for this gender difference is not clear, the level of female steroid hormones or their receptors may be involved in the pathogenesis. The estrogen receptor subtype expressed in the midbrain is limited to the novel beta subtype, whose role in the central nervous system has not been resolved. We demonstrated that ligand-activated estrogen receptor beta suppressed dopaminergic neuronal death in an in vitro Parkinson's disease model which uses 1-methyl-4-phenylpyridinium ions (MPP(+)). MPP(+) treatment caused the upregulation of c-Jun amino-terminal kinase (JNK) and dopaminergic neuronal death, the latter being blocked by curcumin, an inhibitor of the c-Jun/AP-1 cascade. 17alpha- and 17beta-estradiol both protected dopaminergic neurons from MPP(+)-induced neuronal death and this was blocked by a pure antagonist of the estrogen receptor, ICI 182,780, but not by an inhibitor of estrogen receptor dimerization, YP537. These data indicated that the neuroprotection provided by 17alpha-estradiol was via inhibitory transcriptional regulation at the activator protein-1 (AP-1) site mediated by estrogen receptor beta. Thus, 17alpha-estradiol is a suitable candidate for neuroprotective therapy of Parkinson's disease because it is associated with few undesirable feminizing effects.


Asunto(s)
1-Metil-4-fenilpiridinio/efectos adversos , Apoptosis/efectos de los fármacos , Dopamina/metabolismo , Estradiol/farmacología , Estradiol/uso terapéutico , Neuronas/efectos de los fármacos , Trastornos Parkinsonianos/prevención & control , Animales , Apoptosis/fisiología , Muerte Celular/efectos de los fármacos , Muerte Celular/fisiología , Células Cultivadas , Embrión de Mamíferos , Receptor beta de Estrógeno , Femenino , Proteínas Quinasas JNK Activadas por Mitógenos , Mesencéfalo/citología , Mesencéfalo/efectos de los fármacos , Mesencéfalo/metabolismo , Proteínas Quinasas Activadas por Mitógenos/antagonistas & inhibidores , Proteínas Quinasas Activadas por Mitógenos/biosíntesis , Neuronas/citología , Neuronas/metabolismo , Trastornos Parkinsonianos/inducido químicamente , Trastornos Parkinsonianos/metabolismo , Embarazo , Ratas , Receptores de Estrógenos/agonistas , Receptores de Estrógenos/antagonistas & inhibidores , Receptores de Estrógenos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA